35790 Federal Register / Vol. 87, No. 113 / Monday, June 13, 2022 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2021–N–1305] 

Antimicrobial Drug Use in Companion 

Animals; Extension of Comment 

Period 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; extension of comment 

period. 

SUMMARY: The Food and Drug 

Administration (FDA or the Agency) is 

extending the comment period for the 

notice that appeared in the Federal 

Register of February 16, 2022. In that 

notice, FDA requested comments on 

antimicrobial drug use practices in 

companion animals and the potential 

impacts of such uses on antimicrobial 

resistance in both humans and animals. 

The Agency is taking this action in 

response to a request for an extension to 

allow interested persons additional time 

to submit comments. 

DATES: FDA is extending the comment 

period on the notice published February 

16, 2022 (87 FR 8848). Submit either 

electronic or written comments by 

September 14, 2022. 

ADDRESSES: You may submit comments 

as follows. Please note that late, 

untimely filed comments will not be 

considered. Electronic comments must 

be submitted on or before September 14, 

2022. The https://www.regulations.gov 

electronic filing system will accept 

comments until 11:59 p.m. Eastern Time 

at the end of September 14, 2022. 

Comments received by mail/hand 

delivery/courier (for written/paper 

submissions) will be considered timely 

if they are postmarked or the delivery 

service acceptance receipt is on or 

before that date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2021–N–1305 for ‘‘Antimicrobial Drug 

Use in Companion Animals.’’ Received 

comments, those filed in a timely 

manner (see ADDRESSES), will be placed 

in the docket and, except for those 

submitted as ‘‘Confidential 

Submissions,’’ publicly viewable at 

https://www.regulations.gov or at the 

Dockets Management Staff between 9 

a.m. and 4 p.m., Monday through 

Friday, 240–402–7500. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ The 

Agency will review this copy, including 

the claimed confidential information, in 

its consideration of comments. The 

second copy, which will have the 

claimed confidential information 

redacted/blacked out, will be available 

for public viewing and posted on 

https://www.regulations.gov. Submit 

both copies to the Dockets Management 

Staff. If you do not wish your name and 

contact information to be made publicly 

available, you can provide this 

information on the cover sheet and not 

in the body of your comments and you 

must identify this information as 

‘‘confidential.’’ Any information marked 

as ‘‘confidential’’ will not be disclosed 

except in accordance with 21 CFR 10.20 

and other applicable disclosure law. For 

more information about FDA’s posting 

of comments to public dockets, see 80 

FR 56469, September 18, 2015, or access 

the information at: https://

www.govinfo.gov/content/pkg/FR-2015- 

09-18/pdf/2015-23389.pdf. 

Docket: For access to the docket to 

read background documents or the 

electronic and written/paper comments 

received, go to https://

www.regulations.gov and insert the 

docket number, found in brackets in the 

heading of this document, into the 

‘‘Search’’ box and follow the prompts 

and/or go to the Dockets Management 

Staff, 5630 Fishers Lane, Rm. 1061, 

Rockville, MD 20852, 240–402–7500. 

FOR FURTHER INFORMATION CONTACT: 

Barbara Leotta, Center for Veterinary 

Medicine (HFV–110), Food and Drug 

Administration, 7500 Standish Pl., 

Rockville, MD 20855, 240–402–0605, 

barbara.leotta@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of February 16, 2022, 

FDA published a notice with a 120-day 

comment period to request comments 

on antimicrobial drug use practices in 

companion animals and the potential 

impacts of such uses on antimicrobial 

resistance in both humans and animals. 

Comments on antimicrobial use 

practices in companion animals will 

inform FDA’s strategy for promoting 

antimicrobial stewardship in 

companion animals. 

Interested persons were originally 

given until June 16, 2022, to comment 

on the document. The Agency has 

received a request for a 90-day 

extension of the comment period. The 

request conveyed concern that the 

current 120-day comment period does 

not allow sufficient time to develop a 

meaningful or thoughtful response to 

the request for comments. FDA has 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 113 / Monday, June 13, 2022 / Notices 35791 

considered the request and is extending 

the comment period for the request for 

comments for 90 days, until September 

14, 2022. The Agency believes that a 90- 

day extension allows adequate time for 

interested persons to submit comments. 

Dated: June 7, 2022. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2022–12621 Filed 6–10–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Listing of Members of the 

National Institutes of Health’s Senior 

Executive Service 2022 Performance 

Review Board (PRB) 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Institutes of 

Health (NIH) announces the persons 

who will serve on the National 

Institutes of Health’s Senior Executive 

Service 2022 Performance Review 

Board. 

FOR FURTHER INFORMATION CONTACT: For 

further information about the NIH 

Performance Review Board, contact Mr. 

Kha Nguyen, Director, Division of 

Senior and Scientific Executive 

Management, Office of Human 

Resources, National Institutes of Health, 

Building 31, Room 1C31P, Bethesda, 

Maryland 20892, telephone 

301.594.3022 (not a toll-free number), 

email kha.nguyen@nih.gov. 

SUPPLEMENTARY INFORMATION: This 

action is being taken in accordance with 

Title 5, U.S.C., Section 4314(c)(4), 

which requires that members of 

performance review boards be 

appointed in a manner to ensure 

consistency, stability, and objectivity in 

performance appraisals and requires 

that notice of the appointment of an 

individual to serve as a member be 

published in the Federal Register. 

The following persons will serve on 

the NIH Performance Review Board, 

which oversees the evaluation of 

performance appraisals of NIH Senior 

Executive Service (SES) members: 

Alfred Johnson, Chair 

Michael Gottesman 

Darla Hayes 

Michael Lauer 

Kathleen Stephan 

Vicki Buckley 

Rodney Rivera 

Tara Schwetz 

Dated: June 6, 2022. 

Tara A. Schwetz, 

Acting Principal Deputy Director, National 

Institutes of Health. 

[FR Doc. 2022–12603 Filed 6–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Investigator Initiated 

Program Project Applications (P01 Clinical 

Trial Not Allowed). 

Date: July 12, 2022. 

Time: 10:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G45, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Vanitha S. Raman, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G45, Rockville, MD 

20852, 301–761–7949, vanitha.raman@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: June 7, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–12665 Filed 6–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF THE INTERIOR 

Bureau of Land Management 

[LLMTL01000–L161000000.PN0000–223; MO 

#4500161643; MTM–89170–02] 

Notice of Proposed Withdrawal and 

Public Meeting; Montana 

Correction 

In notice document 2022–12103 

beginning on page 34289 in the issue of 

Monday, June 6, 2022, make the 

following correction: 

On page 34290, in the first column, in 

the sixth paragraph, starting on the first 

line ‘‘For a period until June 6, 2024 

including location and entry under the 

United States mining laws, but not from 

leasing under the mineral leasing and 

mineral materials disposal laws, subject 

to valid existing rights, unless the 

application is denied or canceled, or the 

withdrawal is approved prior to that 

date.’’ should read ‘‘For a period until 

June 6, 2024, the public lands described 

earlier will be segregated from all forms 

of appropriation under the public land 

laws, including location and entry 

under the United States mining laws, 

but not from leasing under the mineral 

leasing and mineral materials disposal 

laws, subject to valid existing rights, 

unless the application is denied or 

canceled, or the withdrawal is approved 

prior to that date.’’ 

[FR Doc. C1–2022–12103 Filed 6–10–22; 8:45 am] 

BILLING CODE 1505–01–D 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation No. 337–TA–1319] 

Certain Electronic Devices and 

Semiconductor Devices With TimingAware Dummy Fill and Components 

Thereof; Institution of Investigation 

AGENCY: U.S. International Trade 

Commission. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that a 

complaint was filed with the U.S. 

International Trade Commission on 

April 22, 2022, under section 337 of the 

Tariff Act of 1930, as amended, on 

behalf of Bell Semiconductor, LLC of 

Bethlehem, Pennsylvania. The 

complaint was supplemented on May 6, 

2022, May 13, 2022, and May 19, 2022 

(as revised on May 25, 2022). The 

complaint, as supplemented, alleges 

violations of section 337 based upon the 

importation into the United States, the 

sale for importation, and the sale within 

the United States after importation of 


khammond on DSKJM1Z7X2PROD with NOTICES